Index S&P 500
P/E 28.29
EPS (ttm) 7.90
Insider Own 8.80%
Shs Outstand 728.30M
Perf Week 0.93%
Market Cap 165.14B
Forward P/E 28.55
EPS next Y 7.83
Insider Trans -0.07%
Shs Float 673.87M
Perf Month 17.62%
Income 5.87B
PEG -
EPS next Q 1.87
Inst Own 80.16%
Short Float / Ratio 0.87% / 1.85
Perf Quarter -5.07%
Sales 29.57B
P/S 5.59
EPS this Y -13.46%
Inst Trans -0.22%
Short Interest 5.87M
Perf Half Y 7.46%
Book/sh 70.93
P/B 3.15
EPS next Y -6.82%
ROA 7.01%
Target Price 233.43
Perf Year -7.79%
Cash/sh 16.61
P/C 13.45
EPS next 5Y -1.40%
ROE 11.91%
52W Range 182.09 - 249.55
Perf YTD -5.01%
Dividend 0.93
P/FCF 24.37
EPS past 5Y 22.31%
ROI 8.17%
52W High -10.45%
Beta 0.85
Dividend % 0.42%
Quick Ratio 1.94
Sales past 5Y 12.30%
Gross Margin 58.68%
52W Low 22.73%
ATR 4.85
Employees 81000
Current Ratio 2.26
Sales Q/Q -10.31%
Oper. Margin 23.56%
RSI (14) 68.90
Volatility 1.71% 1.88%
Optionable Yes
Debt/Eq 0.44
EPS Q/Q -28.04%
Profit Margin 19.87%
Rel Volume 0.99
Prev Close 223.31
Shortable Yes
LT Debt/Eq 0.37
Earnings Oct 24 BMO
Payout 10.35%
Avg Volume 3.17M
Price 223.48
Recom 1.62
SMA20 7.58%
SMA50 7.12%
SMA200 3.70%
Volume 3,126,686
Change 0.08%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-19-23 Initiated
Raymond James
Outperform
$270
May-01-23 Initiated
SVB Securities
Outperform
$300
Apr-26-23 Downgrade
BofA Securities
Buy → Neutral
$310 → $250
Apr-18-23 Upgrade
Wells Fargo
Equal Weight → Overweight
$275 → $285
Jan-05-23 Downgrade
Credit Suisse
Outperform → Neutral
$315 → $300
Dec-14-22 Initiated
Deutsche Bank
Buy
$310
Oct-24-22 Downgrade
The Benchmark Company
Buy → Hold
$325
Aug-25-22 Initiated
Credit Suisse
Outperform
$340
Aug-17-22 Resumed
Bernstein
Outperform
$330 → $340
Jul-20-22 Initiated
UBS
Buy
$297
Jun-01-22 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$299 → $310
Apr-25-22 Downgrade
Wells Fargo
Overweight → Equal Weight
$265
Jan-11-22 Initiated
Bernstein
Outperform
$365
Oct-15-21 Resumed
Cowen
Outperform
$350
Sep-10-21 Reiterated
BofA Securities
Buy
$340 → $360
Aug-05-21 Resumed
Credit Suisse
Outperform
$306
Jul-23-21 Reiterated
Goldman
Buy
$280 → $320
Jul-16-21 Initiated
The Benchmark Company
Buy
$330
Apr-07-21 Resumed
Robert W. Baird
Outperform
$249
Mar-03-21 Resumed
Barclays
Overweight
$260
Show Previous Ratings
Nov-29-23 06:00PM
Nov-27-23 10:00AM
Nov-23-23 11:30AM
Nov-22-23 01:13PM
10:05AM
04:15PM
Loading…
Nov-21-23 04:15PM
Nov-20-23 06:52AM
Nov-19-23 07:16PM
Nov-17-23 07:00AM
Nov-16-23 12:01PM
Nov-14-23 09:26AM
Nov-13-23 04:28PM
Nov-10-23 06:10AM
Nov-06-23 04:33PM
04:13PM
04:00PM
Loading…
04:00PM
12:18PM
Nov-05-23 07:08AM
Nov-01-23 05:30PM
02:21PM
07:00AM
Oct-31-23 07:30AM
Oct-27-23 01:21PM
12:43PM
Oct-25-23 11:54AM
Oct-24-23 10:13PM
(Thomson Reuters StreetEvents)
12:56PM
12:13PM
11:58AM
09:35AM
09:30AM
Loading…
09:30AM
07:15AM
06:07AM
(Associated Press Finance)
06:00AM
Oct-23-23 02:00AM
Oct-20-23 06:00PM
04:50AM
Oct-19-23 06:15PM
12:23PM
Oct-16-23 01:12PM
10:35AM
10:22AM
08:05AM
Oct-13-23 06:00PM
Oct-12-23 08:00PM
Oct-10-23 01:24PM
07:00AM
Oct-09-23 07:33AM
Oct-06-23 06:00PM
Oct-05-23 06:15PM
08:00AM
08:00AM
Oct-02-23 08:11PM
04:27PM
Sep-30-23 08:00AM
Sep-29-23 01:13PM
(The Wall Street Journal)
Sep-28-23 06:16PM
02:00AM
12:00AM
Sep-27-23 08:37AM
Sep-26-23 06:15PM
04:15PM
12:08PM
Sep-21-23 03:41PM
Sep-20-23 06:00PM
Sep-19-23 07:43AM
Sep-18-23 06:15PM
Sep-17-23 05:36PM
Sep-14-23 08:28AM
08:01AM
Sep-13-23 09:47PM
11:04AM
04:06AM
Sep-12-23 06:00PM
04:30PM
Sep-08-23 09:14AM
04:00AM
Sep-06-23 06:00PM
11:14AM
Sep-05-23 12:55PM
Sep-03-23 02:00PM
Sep-01-23 12:19PM
Aug-31-23 06:00PM
06:00PM
08:23AM
07:00AM
Aug-29-23 01:51PM
Aug-28-23 04:31PM
01:28PM
09:38AM
09:18AM
08:25AM
(American City Business Journals)
07:42AM
07:34AM
07:30AM
05:56AM
Aug-26-23 10:20AM
Aug-25-23 06:00PM
04:30PM
Aug-16-23 04:30PM
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gutierrez-Ramos Jose-Carlos SVP, Chief Science Officer Aug 21 Sale 250.54 590 147,819 6,939 Aug 22 05:00 PM Raskas Daniel SVP - Corporate Development Jul 28 Option Exercise 56.70 11,213 635,777 49,501 Aug 01 05:03 PM Zerhouni Elias A. Director Jul 28 Option Exercise 50.80 3,490 177,292 30,523 Aug 01 05:02 PM SCHWIETERS JOHN T Director Jul 28 Option Exercise 50.80 3,490 177,292 22,583 Aug 01 05:02 PM FILLER LINDA Director Jul 28 Option Exercise 59.17 2,922 172,895 41,074 Aug 01 05:00 PM Raskas Daniel SVP - Corporate Development Jul 28 Sale 260.65 11,213 2,922,652 38,288 Aug 01 05:03 PM FILLER LINDA Director Jul 28 Sale 260.25 10,190 2,651,978 38,152 Aug 01 05:00 PM Weidemanis Joakim Executive Vice President Jul 26 Option Exercise 56.70 22,439 1,272,291 111,128 Jul 27 05:01 PM List Teri Director Jul 26 Option Exercise 50.80 3,490 177,292 20,984 Jul 27 05:00 PM Weidemanis Joakim Executive Vice President Jul 26 Sale 263.42 22,439 5,910,832 88,689 Jul 27 05:01 PM List Teri Director Jul 26 Sale 263.30 3,490 918,917 17,494 Jul 27 05:00 PM Raskas Daniel SVP - Corporate Development May 31 Option Exercise 57.90 19,847 1,149,141 58,520 Jun 01 05:00 PM Raskas Daniel SVP - Corporate Development May 31 Sale 228.50 19,847 4,535,040 38,673 Jun 01 05:00 PM LOHR WALTER G Director May 05 Option Exercise 50.80 3,490 177,292 15,605 May 08 05:08 PM LOHR WALTER G Director May 05 Sale 240.88 3,490 840,685 12,115 May 08 05:08 PM Weidemanis Joakim Executive Vice President May 04 Option Exercise 57.90 9,934 575,179 101,357 May 05 05:01 PM Weidemanis Joakim Executive Vice President May 04 Sale 245.27 9,934 2,436,512 91,423 May 05 05:01 PM Couchara Georgeann SVP, Human Resources May 04 Sale 245.27 695 170,463 1,565 May 05 05:00 PM Gutierrez-Ramos Jose-Carlos SVP, Chief Science Officer May 01 Sale 242.19 500 121,096 7,529 May 02 05:01 PM Stevens Raymond C Director Jan 25 Option Exercise 101.27 8,410 851,686 11,934 Jan 26 05:06 PM Stevens Raymond C Director Jan 25 Sale 264.27 8,410 2,222,514 8,394 Jan 26 05:06 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite